Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis
Rajiv Radhakrishnan, L. Pries, G. Erzin, M. Ten Have, RON DE Graaf, S. van Dorsselaer, N. Gunther, M. Bak, Bart P. F. Rutten, Jim van Os, S. Guloksuz
Psychological Medicine September 12, 2022 DOI: 10.1017/s0033291722002756 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Longitudinal cohort study (mediation analysis) Peer reviewed |
|---|---|
| Population | Participants in the second Netherlands Mental Health Survey and Incidence Study |
| Topics | Anxiety Cannabis |
| Key findings | The authors report a bidirectional relationship between cannabis use, anxiety/depressive symptoms, and psychotic experiences. Cannabis use mediated the path from earlier anxiety or depression to later psychotic experiences only slightly (1.00% and 1.4% of the total effect, respectively), whereas anxiety and depressive symptoms mediated the path from earlier cannabis use to later psychotic experiences more strongly (17% and 37%, respectively). |
Abstract
Abstract Background Empirical evidence suggests that people use cannabis to ameliorate anxiety and depressive symptoms, yet cannabis also acutely worsens psychosis and affective symptoms. However, the temporal relationship between cannabis use, anxiety and depressive symptoms and psychotic experiences (PE) in longitudinal studies is unclear. This may be informed by examination of mutually mediating roles of cannabis, anxiety and depressive symptoms in the emergence of PE.
Methods: Data were derived from the second longitudinal Netherlands Mental Health Survey and Incidence Study. Mediation analysis was performed to examine the relationship between cannabis use, anxiety/depressive symptoms and PE, using KHB logit in STATA while adjusting for age, sex and education status.
Results: Cannabis use was found to mediate the relationship between preceding anxiety, depressive symptoms and later PE incidence, but the indirect contribution of cannabis use was small (for anxiety: % of total effect attributable to cannabis use = 1.00%; for depression: % of total effect attributable to cannabis use = 1.4%). Interestingly, anxiety and depressive symptoms were found to mediate the relationship between preceding cannabis use and later PE incidence to a greater degree (% of total effect attributable to anxiety = 17%; % of total effect attributable to depression = 37%).
Conclusion: This first longitudinal cohort study examining the mediational relationship between cannabis use, anxiety/depressive symptoms and PE, shows that there is a bidirectional relationship between cannabis use, anxiety/depressive symptoms and PE. However, the contribution of anxiety/depressive symptoms as a mediator was greater than that of cannabis.
Comparable studies
Other observational and cohort studies on cannabis for anxiety, most cited first.
Citations in the library
Cited by 4
- Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort Psychiatry Research May 8, 2023
- Candidate Targets for Resilience Training to Reduce Transdiagnostic Risk for Mental Illness. Schizophrenia Bulletin June 17, 2025
- Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool. Psychological Medicine 2024
- The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case–control study Psychological Medicine May 2, 2023
Cites 2
- Schizophrenia and the Environment: Within-Person Analyses May be Required to Yield Evidence of Unconfounded and Causal Association—The Example of Cannabis and Psychosis Schizophrenia Bulletin March 8, 2021
- The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study The Lancet Psychiatry May 1, 2019